Chemotherapy (CT) +/- pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase 3 trial
ONCOLOGY RESEARCH AND TREATMENT（2016）
Key words
ovarian cancer,pertuzumab,chemotherapy,platinum-resistant,ago-ovar,double-blind,placebo-controlled
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined